Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.

In conclusion, the SAW-CT assay is capable to monitor anticoagulant level and effect in patients receiving dabigatran, rivaroxaban and the VKA phenprocoumon. It has a limited sensitivity for apixaban-detection. If specific SAW-CT results were used as cut-offs, SAW-CT yields high diagnostic accuracy to exclude relevant rivaroxaban and dabigatran concentrations in stroke-patients.
PMID: 28124061 [PubMed - as supplied by publisher]

Source: Thrombosis and Haemostasis - January 25, 2017 Category: Hematology Authors: Bluecher A, Meyer Dos Santos S, Ferreirós N, Labocha S, Meyer Dos Santos IM, Picard-Willems B, Harder S, Singer OC Tags: Thromb Haemost Source Type: research